BPC 157 is primarily studied for tissue healing and anti-inflammatory effects
The good news is that your body can produce and restore its glutathione levels
The FDAs Stance and Why It Misses the Mark In 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance , meaning it raises significant safety concerns. The agency specifically cited risks of immunogenicity , peptide-related impurities , and lack of sufficient safety data for human use
For people who want a broader view of peptide options, the peptide therapy page shows how Livv groups peptides by goals
Proteolysis of tilapia skin collagen: identification and release behavior of ACE-inhibitory peptides
Conclusions Given that cellular senescence, inflammaging, and counteracting immune suppression increase with aging, this might explain why excessive insulin/IGF-1 signaling promotes the aging process